Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Cited by (1,001)

Items 601–700 of 1,001

1. Neutralizing antibody responses to three XBB protein vaccines in older adults
   Guojian Yang, Mei Lu, Rui-Rui Chen, Shuang-Qing Wang, Sheng Wan, Xuedong Song, Guo-Ping Cao, Lei Lv, Xue-Juan He, Bingdong Zhan et al. · 2025 · Signal Transduction and Targeted Therapy
2. Serum anti-nucleocapsid antibody correlates of protection from SARS-CoV-2 re-infection regardless of symptoms or immune history
   Shô Miyamoto, Koki Numakura, Ryo Kinoshita, Takeshi Arashiro, Hiromizu Takahashi, Hiromi Hibino, Minako Hayakawa, Takayuki Kanno, Akiko Sataka, Rena Sakamoto et al. · 2025 · Communications Medicine
3. The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year
   Xinrong Zhou, Lin Cheng, Haiyan Wang, Xuejiao Liao, Miao Wang, Lanlan Wei, Shuo Song, Bing Zhou, Zhenghua Ma, Huimin Guo et al. · 2022 · Emerging Microbes & Infections
4. Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern
   Erika Rudi, Pablo Martín Aispuro, Eugenia Zurita, María Mora González López Ledesma, Daniela Bottero, Juan Pablo Malito, Magalí Gabrielli, María Emilia Gaillard, Matthew Stuible, Yves Durocher et al. · 2022 · Frontiers in Immunology
5. Dose optimisation and scarce resource allocation: two sides of the same coin
   Garth William Strohbehn, Govind Persad, William F. Parker, Srinivas Murthy · 2022 · BMJ Open
6. SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study
   Victoria Ward, Jia Wei, William Gordon, Eleanor J. Barnes, Susanna Jane Dunachie, Katie JM Jeffery, David W. Eyre, Anne-Marie O’Donnell · 2022 · BMJ Open
7. Distinct doorway states lead to triplet excited state generation in epigenetic RNA nucleosides
   Danhong Wang, Xueli Wang, Peipei Jin, Yusong Zhou, Menghui Jia, Hai‐Feng Pan, Zhenrong Sun, Jinquan Chen · 2023 · Physical Chemistry Chemical Physics
8. Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti–SARS-CoV-2 antibodies in the absence of CXCL13
   Marne Azarias-da-Silva, Pierre Nioche, Calaiselvy Soudaramourty, Anne Bull-Maurer, Mounira Tiouajni, Dechuan Kong, Ouafa Zghidi‐Abouzid, Morgane Picard, Ana Mendes‐Frias, André Santa Cruz et al. · 2023 · Science Advances
9. Sustained S-IgG and S-IgA antibodies to Moderna’s mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations
   Jennifer Serwanga, Violet Ankunda, Joseph Ssebwana Katende, Claire Baine, Gerald Kevin Oluka, Geoffrey Odoch, Hellen Nantambi, Susan Mugaba, Angella Namuyanja, Ivan Ssali et al. · 2024 · Frontiers in Immunology
10. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada
    Henintsoa Rabezanahary, Caroline Gilbert, Kim Santerre, Martina Scarrone, Mégan Gilbert, Mathieu Thériault, Nicholas Brousseau, Jean‐François Masson, Joelle N. Pelletier, Denis Boudreau et al. · 2024 · Heliyon
11. A quadri-fluorescence SARS-CoV-2 pseudovirus system for efficient antigenic characterization of multiple circulating variants
    Jijing Chen, Zehong Huang, Jin Xiao, Shuangling Du, Qingfang Bu, Huilin Guo, Jianghui Ye, Shiqi Chen, Jiahua Gao, Zonglin Li et al. · 2024 · Cell Reports Methods
12. First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster
    Meral Esen, Johanna Fischer-Herr, Julian Justin Gabor, Marika Gaile, Wim Alexander Fleischmann, Geerten Willem Smeenk, Roberta Allgayer de Moraes, Sabine Bélard, Carlos Lamsfus Calle, Tamirat Gebru Woldearegai et al. · 2024 · Vaccines
13. Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine
    Zhifei Chen, Fangqin Xie, Hairong Zhang, Li Dong, Suhan Zhang, Mengping Zhang, Junrong Li, Jianfeng Xie, Lina Zhang, Xiuhui Yang et al. · 2025 · Frontiers in Public Health
14. Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy
    Immacolata Polvere, Alfredina Parrella, Lucrezia Zerillo, Serena Voccola, Gaetano Cardinale, Silvia D’Andrea, Jessica Raffaella Madera, Romania Stilo, Pasquale Vito, Tiziana Zotti · 2022 · Frontiers in Immunology
15. Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals
    James N. Moy, Mark Anderson, Xiaoying Shen, Jia Fu, Michael Stec, Amy Gosha, Dina Naquiallah, Jennifer D. Kinslow, David C. Montefiori, Gavin Cloherty et al. · 2022 · The Journal of Infectious Diseases
16. Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials
    Umaporn Siangphoe, Lindsey Robert Baden, Hana M. El Sahly, Brandon J. Essink, Kashif Ali, Gary Berman, Joanne E. Tomassini, Weiping Deng, Rolando Pajón, Roderick A. McPhee et al. · 2022 · Clinical Infectious Diseases
17. Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
    Pingchao Li, Qian Wang, Yizi He, Chenchen Yang, Zhengyuan Zhang, Zijian Liu, Bo Liu, Li Yin, Yilan Cui, Peiyu Hu et al. · 2022 · Emerging Microbes & Infections
18. Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study
    Kei Nakashima, Masayuki Ishida, Hiroki Matsui, Chihiro Yoshida, Tatsuya Nagai, Minoru Shiraga, Hiroshi Nakaoka, Yoshihito Otsuka, Yu Nakagama, Natsuko Kaku et al. · 2022 · Human Vaccines & Immunotherapeutics
19. Tale of the Titers: Serologic Testing for SARS-CoV-2—Yes, No, and Maybe, With Clinical Examples From the IDSA Diagnostics Committee
    Robert C. Colgrove, Lou Ann Bruno‐Murtha, Cody A. Chastain, Kimberly E. Hanson, Francesca Lee, Audrey R. Odom John, Romney M. Humphries · 2022 · Open Forum Infectious Diseases
20. Assessing Vulnerability to COVID-19 in High-Risk Populations: The Role of SARS-CoV-2 Spike-Targeted Serology
    Harvey W. Kaufman, William A. Meyer, Nigel J. Clarke, Jeff S. Radcliff, Christopher M. Rank, James Freeman, Marcia T. Eisenberg, Laura Gillim, William George Morice, David Michael Briscoe et al. · 2023 · Population Health Management
21. Update on Covid-19: vaccines, timing of transplant after COVID-19 infection and use of positive donors
    Catherine-Audrey Boutin, Maha Al‐Amri, Michael G. Ison · 2023 · Current Opinion in Organ Transplantation
22. SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers
    Eun‐Hee Nah, Seon Cho, Hyeran Park, Suyoung Kim, Dongwon Noh, Eunjoo Kwon, Han‐Ik Cho · 2023 · Viruses
23. Progress in vaccine development for infectious diseases—a Keystone Symposia report
    Jennifer Cable, Barney S. Graham, Richard A. Koup, Robert A. Seder, Katalin Karikó, Norbert Pardi, Dan H. Barouch, Bhawna Sharma, Susanne Rauch, Raffael Nachbagauer et al. · 2023 · Annals of the New York Academy of Sciences
24. Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy
    Madison Stoddard, Lin Yuan, Sharanya Sarkar, Shruthi Mangalaganesh, Ryan P. Nolan, Dean C. Bottino, Greg Hather, Natasha S. Hochberg, Laura Forsberg White, Arijit Chakravarty · 2023 · Vaccines
25. Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19
    Yaling An, Gan Zhao, Huixin Duan, Ning Zhang, Minrun Duan, Senyu Xu, Xueyuan Liu, Yuxuan Han, Tianyi Zheng, Xin Li et al. · 2023 · Journal of Medical Virology
26. Association between levels of IgG antibodies from vaccines and Omicron symptomatic infection among children and adolescents in China
    Xinying Chen, Junbin Hong, Li-Jun Deng, Heng Weng, Teng Huang, Wang Li, Aihua Ou, Yuxia Li, Bo Yu, Jianwen Guo et al. · 2023 · Frontiers in Medicine
27. Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans
    Anna Dari, Philippe Jacqmin, Yuki Iwaki, Martine Neyens, Mathieu Le Gars, JERALD C. SADOFF, Karin Hardt, Javier Ruiz‐Guiñazú, Juan José Pérez Ruixo · 2023 · CPT Pharmacometrics & Systems Pharmacology
28. Hybrid Immunity Improves the Immune Response after the Fourth COVID-19 Vaccine Dose in Individuals with Medical Conditions Predisposing to Severe COVID-19
    Nina Ekström, Tuija M. Leino, Aapo Juutinen, Toni Lehtonen, Anu Haveri, Oona Liedes, Saimi Vara, Heini Salo, ARTO A. I. PALMU, Hanna Nohynek et al. · 2024 · Vaccines
29. Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose
    Geert V.T. Roozen, Manon L. M. Prins, Corine Prins, Jacqueline J. Janse, Heidi L. M. De Gruyter, Cilia R. Pothast, Wesley Huisman, Jan Pieter R. Koopman, Olivia A. C. Lamers, Marjan Kuijer et al. · 2024 · Clinical Microbiology and Infection
30. Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial
    Flonza Isa, Ana M. Gonzalez Ortiz, Jonathan Meyer, Jennifer D. Hamilton, Benjamin A. Olenchock, Taylor Brackin, Samit Ganguly, Eduardo Forleo‐Neto, Lori Faria, Ingeborg Heirman et al. · 2024 · The Lancet Infectious Diseases
31. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants
    Hoi Lok Cheng, Sing Mei Lim, Huan Jia, Ming Wei Chen, Say Yong Ng, Xiaohong Gao, Jyoti Somani, Sharmila Sengupta, Dousabel M. Y. Tay, Patrina Wei Lin Chua et al. · 2022 · Microbiology Spectrum
32. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike
    Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, Nincy Debeuf, Sahine Lameire, Wim Nerinckx, Kenny Roose, Daria Fijałkowska et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
33. Serum Concentration of Antigen-Specific IgG Can Bias Interpretation of the Readout of Antibody-Dependent Phagocytosis Assay
    Russell St. Germain, Emily L. Bossard, Lawrence Corey, Anton M. Sholukh · 2022 · iScience
34. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations
    Elizabeth Titova, Veronica W. Kan, Tara Lozy, Andrew Ip, Kileen L. Shier, Vittal P. Prakash, Meghan W. Starolis, Sara Ansari, Kira Goldgirsh, Seoyeon Kim et al. · 2024 · Microbiology Spectrum
35. Convergence of SARS-CoV-2 spike antibody levels to a population immune setpoint
    Eric James Nilles, Kathryn W. Roberts, Michael de St. Aubin, Helen J. Mayfield, Angela Cadavid Restrepo, Salomé Garnier, Gabriela Abdalla, Marie Caroline Etienne, William Duke, Devan Dumas et al. · 2024 · EBioMedicine
36. CoronaVac-induced antibodies that facilitate Fc-mediated neutrophil phagocytosis track with COVID-19 disease resolution
    Chuang Li, Jie Yu, Rahma Issa, Lili Wang, Mingzhe Ning, Shengxia Yin, Jie Li, Chao Wu, Yuxin Chen · 2024 · Emerging Microbes & Infections
37. Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia
    Marianna Karachaliou, Ana Espinosa, Xavier Farré, Natàlia Blay, Gemma Castaño‐Vinyals, Susana Iraola‐Guzmán, Rocío Rubio, Marta Vidal, Alfons Jiménez, Marc Bañuls et al. · 2024 · Vaccine
38. Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens
    Pedro Cruz, Jie Min Lam, Jehad Abdalla, Samira Bell, Jola Bytyci, Tal Brosh‐Nissimov, John S. Gill, Ghady Haidar, Michael P. Hoerger, ‪Yasmin Maor‬‏ et al. · 2024 · Vaccines
39. A systems biology approach to define SARS-CoV-2 correlates of protection
    Caolann Brady, Tom Tipton, Oliver T. Carnell, Stéphanie Longet, Karen E. Gooch, Yper Hall, Javier Salguero, Adriana Tomić, Miles W. Carroll · 2025 · npj Vaccines
40. Evolution of the PRNT: Merging tradition and innovation to set the gold standard in the era of automation
    Caio Bidueira Denani, Ingrid Siciliano Horbach, Bruno Pimenta Setatino, Adriana de Souza Azevedo, Sheila Maria Barbosa de Lima, Waleska Dias Schwarcz, Ivanildo Pedro de Sousa Junior · 2025 · Human Vaccines & Immunotherapeutics
41. Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling
    Caio Bidueira Denani, Bruno Pimenta Setatino, Denise Pereira, Ingrid Siciliano Horbach, Adriana de Souza Azevedo, Gabriela Coutinho, Clara Lucy de Vasconcellos Ferroco, Janaína Reis Xavier, Robson Leite, Ewerton Alves Portela dos Santos et al. · 2025 · Pathogens
42. Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination
    Mohammad‐Shafi Mojadadi, Seyed Alireza Javadinia, Fahimeh Attarian, Elham Samami, Mona Sobhani · 2023 · Frontiers in Public Health
43. A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile
    Gérémy Sannier, Alexandre Nicolas, Mathieu Dubé, Lorie Marchitto, Manon Nayrac, Olivier Tastet, Debashree Chatterjee, Alexandra Tauzin, Raphaël Lima-Barbosa, Mélanie Laporte et al. · 2023 · Cell Reports Medicine
44. Aerosol Inhalation of Chimpanzee Adenovirus Vectors (ChAd68) Expressing Ancestral or Omicron BA.1 Stabilized Pre–Fusion Spike Glycoproteins Protects Non–Human Primates against SARS-CoV-2 Infection
    Shen Wang, Mian Qin, Long Xu, Ting Mu, Ping Zhao, Bing Sun, Yue Wu, Lingli Song, Han‐Chung Wu, Weicheng Wang et al. · 2023 · Vaccines
45. Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals
    Eugenia Galeota, Valeria Bevilacqua, Andrea Gobbini, Paola Gruarin, Mauro Bombaci, Elisa Pesce, Andrea Favalli, Andrea Lombardi, Francesca Vincenti, Jessica Ongaro et al. · 2024 · Clinical Immunology
46. Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy
    Min Joo Choi, Hakjun Hyun, Jung Yeon Heo, Yu Bin Seo, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Hwa Jung Kim, Ju‐Yeon Choi, Young Jae Lee et al. · 2024 · Heliyon
47. NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
    Franz Mai, Marcel Kordt, Wendy Bergmann‐Ewert, Emil Christian Reisinger, Brigitte Müller‐Hilke · 2024 · Frontiers in Immunology
48. Validation of a severe acute respiratory syndrome coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity
    Stephanie Hamilton, Mingzhu Zhu, Shane Cloney-Clark, Penny Mayes, Jen Fenner, Leah Cui, Rongman Cai, Raj Kalkeri, Louis F Fries, Melinda Pryor et al. · 2024 · Journal of Virological Methods
49. Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors
    Mhairi J. McCormack, Patawee Asamaphan, Ellen C. Hughes, Louis Banda, Stephen Kasenda, Christopher Davis, Agnieszka M. Szemiel, Amelia Catharine Crampin, Abena Serwaa Amoah, Emma C. Thomson et al. · 2025 · Scientific Reports
50. Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
    Maxime Jullien, Marianne Coste‐Burel, Béatrice Clemenceau, Valentin Letailleur, Thierry Guillaume, Pierre Péterlin, Alice Garnier, Amandine Le Bourgeois, Berthe‐Marie Imbert, Jocelyn Ollier et al. · 2022 · eJHaem
51. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
    Pablo Hernández-Luis, Ruth Aguilar, Judit Pelegrin-Pérez, Gemma Ruiz‐Olalla, Alberto L. García‐Basteiro, Marta Tortajada, Gemma Moncunill, Carlota Dobaño, Ana Angulo, Pablo Engel · 2022 · Frontiers in Immunology
52. Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies
    Gianfranco Alicandro, Valeria Daccò, Lisa Cariani, Chiara Rosazza, Calogero Sathya Sciarrabba, Federica Ferraro, Chiara Lanfranchi, Paola Medino, Daniela Girelli, Carla Colombo · 2022 · Biomedicines
53. Impact of COVID‐19 vaccination on transmission risk of breakthrough infections: Lessons from adapted N95 mask sampling for emerging variants and interventions
    Kalpana Sriraman, Ambreen Shaikh, Smriti Vaswani, Tejal Mestry, Grishma Patel, Shalini Sakthivel, Vikas Oswal, Pratibha Kadam, Kayzad Soli Nilgiriwala, Daksha Shah et al. · 2022 · Journal of Medical Virology
54. Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy
    Isabel Hodl, Clarissa Sallegger, Patrick Forstner, Nazanin Sareban, Martina Moritz, Barbara Dreo, Eduard Schulz, Angelika Lackner, Barbara Kleinhappl, Stefan Hatzl et al. · 2023 · Microbes and Infection
55. Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach
    Erin Williams, Alexander Kizhner, Valerie S. Stark, Aria Nawab, Daniel D. Muniz, Felipe Echeverri Tribin, Juan Manuel Carreño, Dominika A. Bielak, Gagandeep Singh, Michael E. Hoffer et al. · 2023 · Frontiers in Immunology
56. Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
    Lorenza Bellusci, Hana Golding, Surender Khurana · 2023 · Journal of Clinical Investigation
57. Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study
    Héctor Meijide Míguez, Iñaki Montes García, Miguel Ochando Gómez, Isabel M. García Merino, Emilio L. Cano, Alejandro de la Torre · 2023 · Revista Española de Geriatría y Gerontología
58. Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C)
    Maria A. Perez, Hui‐Mien Hsiao, Xuemin Chen, Amber Kunkel, Nadine Baida, Laila Hussaini, Austin Lu, Carol M. Kao, Federico R. Laham, David A. Hunstad et al. · 2023 · Vaccine
59. Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern
    Javier García‐Pérez, Mercedes Bermejo, Almudena Ramírez‐García, Erick De La Torre Tarazona, Almudena Cascajero, María Castillo de la Osa, Paloma Jiménez, Marta Aparicio Gómez, Esther Calonge, Aránzazu Sancho‐López et al. · 2023 · Journal of Medical Virology
60. SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients
    Afoke Kokogho, Trevor A. Crowell, Muneerah M Aleissa, Ana‐Mihaela Lupan, Sonya Davey, Jun Bai Park Chang, Lindsey Robert Baden, Stephen R. Walsh, Amy C Sherman · 2023 · Open Forum Infectious Diseases
61. Determinants of protection against SARS‐CoV‐2 Omicron BA.1 and Delta infections in fully vaccinated outpatients
    Alvaro Roy, Carla Saade, Laurence Josset, Bénédicte Clement, Florence Morfin, Grégory Destras, Martine Valette, Vinca Icard, Geneviève Billaud, Antoine Oblette et al. · 2023 · Journal of Medical Virology
62. Respiratory viral infections in the elderly: From the perspective of the aging immune system
    Xueyang Zhang, Jiuyang Xu, Yeming Wang, Hui Li, Jiapei Yu, Lianhan Shang, Lianhan Shang, Baidong Hou, Xulong Zhang, Bin Cao · 2023 · The Innovation Medicine
63. Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients
    Ahram Han, Sangil Min, Eun-Ah Jo, Hajeong Lee, Yong Chul Kim, Seung Seok Han, Hee Gyung Kang, Yo Han Ahn, Inseong Oh, Eun Young Song et al. · 2023 · Annals of Laboratory Medicine
64. Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis
    Jenna M. Benoit, Jessica A. Breznik, Jann Catherine Ang, Hina Bhakta, Angela Huynh, Braeden Cowbrough, Barbara Baker, Lauren Heessels, Sumiya Lodhi, Elizabeth Yan et al. · 2023 · Scientific Reports
65. Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection
    Mohamed I. M. Ahmed, Sebastian Einhauser, Clemens Peiter, Antonia Senninger, Olga Baranov, Tabea M. Eser, Manuel Huth, Laura Olbrich, Noemi Castelletti, Raquel Rubio‐Acero et al. · 2024 · iScience
66. Time course of antibody concentrations against the spike protein of SARS‐CoV‐2 among healthy hospital workers up to 200 days after their first COVID‐19 vaccination
    Thomas Mueller · 2021 · Journal of Clinical Laboratory Analysis
67. Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19
    Aiquan Chang, Jingyou Yu · 2022 · Viruses
68. Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19
    Paulina Kapłonek, Deniz Cizmeci, Jessica Shih-Lu Lee, Sally A. Shin, Stephanie Fischinger, Philipe Gobeil, Stéphane Pillet, Nathalie Charland, Brian J. Ward, Galit Alter · 2023 · npj Vaccines
69. Pre-clinical models to define correlates of protection for SARS-CoV-2
    Caolann Brady, Tom Tipton, Stéphanie Longet, Miles W. Carroll · 2023 · Frontiers in Immunology
70. Immunity Induced by Inactivated SARS-CoV-2 Vaccine: Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort
    Ying Chen, Caiqin Hu, Zheng Wang, Junwei Su, Shuo Wang, Bin Li, Xiang Liu, Zhenzhen Yuan, Dan Li, Hong Wang et al. · 2023 · Pathogens
71. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway
    Matthew Gagné, Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, Danielle A. Wagner, Shayne F. Andrew, John-Paul M. Todd, Christopher Cole Honeycutt, Lauren McCormick, Saule T. Nurmukhambetova et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
72. Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variants
    Trung The Tran, Eline Benno Vaage, Adi Mehta, Adity Chopra, Anette Kolderup, Aina Karen Anthi, Marton Skog Steinberger König, Gro Owren Nygaard, Andreas Lind, Fredrik Müller et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
73. Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study
    Shona C. Moore, Barbara Kronsteiner, Stéphanie Longet, Sandra Adele, Alexandra S. Deeks, Chang Liu, Wanwisa Dejnirattisai, Laura Silva-Reyes, Naomi Meardon, Sian Elizabeth Faustini et al. · 2022 · medRxiv
74. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
    Timothy J.C. Tan, Zongjun Mou, Ruipeng Lei, Wenhao O. Ouyang, Meng Yuan, Ge Song, Raiees Andrabi, Ian A. Wilson, Collin Kieffer, Xinghong Dai et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
75. Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera
    Wei Wang, Gitanjali L. Bhushan, Stephanie Paz, Charles B. Stauft, Prabhu Selvaraj, Emilie Goguet, Kimberly A. Bishop‐Lilly, Rahul Subramanian, Russell A. Vassell, Sabrina Lusvarghi et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
76. Kinetics of neutralising antibodies against Omicron variant in Vietnamese healthcare workers after primary immunisation with ChAdOx1-S and booster with BNT162b2
    Nguyen Van Vinh Chau, Lam Anh Nguyet, Nguyen Thanh Dung, Vo Minh Quang, Nguyen Thanh Truong, Le Mau Toan, Le Manh Hung, Dinh Nguyen Huy Man, Dao Bach Khoa, Nguyen Thanh Phong et al. · 2022 · medRxiv
77. Immune imprinting and antibody profiles to SARS-CoV-2 in urban and rural Ghana
    Martin Montiel-Ruiz, Elvis Suatey Lomotey, Elizabeth Obeng-Aboagye, Isaac Kweku Quaye, Daniel Adjei Odumang, Florence B Amakye, Bernard A. Logonia, Salomé Lochmann, Joseph A Hayford, Dickson Osabutey et al. · 2025 · iScience
78. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada
    Cecilia Theresa Costiniuk, Joel Singer, Terry Lee, Yannick Galipeau, Pauline S. McCluskie, Corey R. Arnold, Marc‐André Langlois, Judy Needham, Mohammad-Ali Jenabian, Ann N. Burchell et al. · 2023 · AIDS
79. Impact of the COVID-19 vaccine booster strategy on vaccine protection: a pilot study of a military hospital in Taiwan
    Yuli Wang, Shu-Tsai Cheng, Ching‐Fen Shen, Shu-Wei Huang, Chao‐Min Cheng · 2023 · Clinical and Experimental Vaccine Research
80. Antigen-specific T cell responses in SARS-CoV-2 mRNA-vaccinated children
    Jordan D. Philpott, Jordan D. Miller, Brittany P. Boribong, Saeina Charles, Jameson P. Davis, Simon Kazimierczyk, Brittany Jimena, Maureen M. Leonard, Wayne G. Shreffler, Alessio Fasano et al. · 2023 · Cell Reports Medicine
81. The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)
    Martina Frodlund, Per Nived, Katerina Chatzidionysiou, Anna Södergren, Eva Klingberg, Monica Hansson, Sophie Ohlsson, Elisa Pin, Anders A Bengtsson, Lars Klareskog et al. · 2024 · Microbiology Spectrum
82. T Cell Peptide Prediction, Immune Response, and Host–Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects
    Iole Macchia, Valentina La Sorsa, Alessandra Ciervo, Irene Ruspantini, Donatella R. M. Negri, Martina Borghi, Maria Laura De Angelis, Francesca Luciani, Antonio Martina, Silvia Taglieri et al. · 2024 · Biomolecules
83. Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration
    Tara M Babu, Lisa A. Jackson, Hana M. El Sahly · 2024 · The Journal of Infectious Diseases
84. SARS-CoV-2 SPIKE Antibody Levels can Indicate Immuno-Resilience to Re-infection: a Real-World Study
    Yue Jin, Fei Yang, Christopher M. Rank, Stanley I. Letovsky, Peter Ramge, Simon Jochum · 2024 · Infectious Diseases and Therapy
85. SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol
    Vivienne C. Bachelet, Ignacio Silva-Ayarza, Francisca J Lizana, Patricio Gomolan G., Diego Silva-Villalobos, María Soledad Navarrete · 2022 · BMJ Open
86. Serologic Tests for COVID-19 Infections and Vaccination
    Stanley Alan Plotkin · 2022 · The Pediatric Infectious Disease Journal
87. Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2
    Erin Williams, Jordan Colson, Ranjini Valiathan, Juan Manuel Carreño, Florian Krammer, Michael E. Hoffer, Suresh Pallikkuth, Savita G. Pahwa, David M Andrews · 2022 · Vaccine
88. Boosting with updated COVID-19 mRNA vaccines
    Deepta Bhattacharya, Gabriel D. Victora · 2022 · Nature Medicine
89. Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis
    Gianfranco Alicandro, Béatrice Silvia Orena, Chiara Rosazza, Lisa Cariani, Maria Chiara Russo, Michela Zatelli, Raffaele Badolato, Andrea Gramegna, Francesco Blasi, Valeria Daccò · 2023 · Vaccine
90. Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus
    Christine Parsons, Jose Rubio, Afroditi Boulougoura, Suzanne Krishfield, Vasileios C. Kyttaris · 2023 · Rheumatology International
91. Homologous or heterologous COVID-19 vaccine schemes: comparison of immune responses and side effects
    Rıdvan Karaali, Harika Öykü Dinç, İ̇lker İnanç Balkan, Günay Can, Elif Keskin, Hatice Çolak, Ferhat Osman Daşdemir, Okan Aydoğan, Beyhan Budak, Sibel Yıldız Kaya et al. · 2023 · Diagnostic Microbiology and Infectious Disease
92. Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants
    Yan Ling Wu, Jian R. Shi, Xiaoxue He, Jia Lu, Xiao Gao, Xuerui Zhu, Xinlan Chen, Man Zhang, Lijuan Fang, Jing Zhang et al. · 2023 · Journal of Virology
93. Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection
    John T. Bates, Seth T. Lirette, Andrew P. Farmer, Michael A. Bierdeman, Kristina B. Seyfarth, Dallas R. Ederer, Denise D. Montgomery, Grace C. Burnett, Amanda T. Pham, Gailen D. Marshall · 2024 · Human Vaccines & Immunotherapeutics
94. Serological Correlates of Protection Induced by COVID-19 Vaccination in the Working Age Population: A Systematic Review and Meta-Analysis
    Alborz Rahmani, Alfredo Montecucco, Luca Priano, Lucia Mandolini, Guglielmo Dini, Paolo Durando · 2024 · Vaccines
95. Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Tomoyuki Kakugawa, Yusuke Mimura, Yuka Mimura‐Kimura, Keiko Doi, Yuichi Ohteru, Hiroyuki Kakugawa, Keiji Oishi, Masahiro Kakugawa, Tsunahiko Hirano, Kazuto Matsunaga · 2024 · Immunity & Ageing
96. COVID ‐19 vaccinated children, adolescents, and young adults with acute lymphoblastic leukemia show spike reactive antibodies and multifunctional T‐cells
    Rebecca S Parker, Justin Le, Miguel Villa, Annie Luong, Tsen Yin Lin, Yesun Lee, Andrew Doan, Paibel Ixia Aguayo-Hiraldo, Pia S. Pannaraj, Seon‐Jae Yoon et al. · 2024 · International Journal of Cancer
97. The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2
    Manish K. Dhawan, Nanamika Thakur, Manish Kumar Sharma, Ali Ahmed Rabaan · 2025 · Biomedicine & Pharmacotherapy
98. Low Levels of Neutralizing Antibodies Against SARS‐CoV‐2 KP.3.1.1 and XEC in Serum From Seniors in May 2024
    Even Fossum, Elisabeth Lea Vikse, Anna Hayman Robertson, Asia‐Sophia Wolf, Andreas Rohringer, Lill Trogstad, Siri Mjaaland, Olav Hungnes, Karoline Bragstad · 2025 · Influenza and Other Respiratory Viruses
99. Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
    Christine M. Akamine, Hana M. El Sahly · 2021 · Translational research
100. Saliva-based SARS-CoV-2 serology using at-home collection kits returned via mail
     Christopher Campbell, Douglas W. Roblin, Nikhil Padmanabhan, Daniel Romero, Jessica Joe, Lily Fathi, Thomas Whiting, Jared N. Williamson, Paul Goodwin, Charmaine Mckie et al. · 2022 · Scientific Reports